Cargando…
Characterization of Dosage Levels for In Ovo Administration of Innate Immune Stimulants for Prevention of Yolk Sac Infection in Chicks
Innate immune stimulants, especially toll-like receptor (TLR) ligands and agonists, are the main players in the initiation of innate immunity and have been widely studied as alternatives to antibiotics to control infection. In the present study, we characterized the dosage levels of various innate i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142911/ https://www.ncbi.nlm.nih.gov/pubmed/35622731 http://dx.doi.org/10.3390/vetsci9050203 |
_version_ | 1784715676172156928 |
---|---|
author | Sarfraz, Mishal Nguyen, Thuy Thi Thu Wheler, Colette Köster, Wolfgang Gerdts, Volker Dar, Arshud |
author_facet | Sarfraz, Mishal Nguyen, Thuy Thi Thu Wheler, Colette Köster, Wolfgang Gerdts, Volker Dar, Arshud |
author_sort | Sarfraz, Mishal |
collection | PubMed |
description | Innate immune stimulants, especially toll-like receptor (TLR) ligands and agonists, are the main players in the initiation of innate immunity and have been widely studied as alternatives to antibiotics to control infection. In the present study, we characterized the dosage levels of various innate immune stimulants, including unmethylated cytosine-phosphate-guanosine dinucleotide -containing oligodeoxynucleotides (CpG ODN), polyinosinic-polycytidylic acid (poly I:C), cyclic polyphosphazene 75B (CPZ75B), avian beta-defensin 2 (ABD2), and combinations of these reagents given in ovo. Data derived from a series of animal experiments demonstrated that the in ovo administration of 10–50 µg CpG ODN/embryo (on embryonic day 18) is an effective formulation for control of yolk sac infection (YSI) due to avian pathogenic Escherichia coli (E. coli) in young chicks. Amongst the different combinations of innate immune stimulants, the in ovo administration of CpG ODN 10 µg in combination with 15 µg of poly I:C was the most effective combination, offering 100% protection from YSI. It is expected that the introduction of these reagents to management practices at the hatchery level may serve as a potential replacement for antibiotics for the reduction of early chick mortality (ECM) due to YSI/colibacillosis. |
format | Online Article Text |
id | pubmed-9142911 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91429112022-05-29 Characterization of Dosage Levels for In Ovo Administration of Innate Immune Stimulants for Prevention of Yolk Sac Infection in Chicks Sarfraz, Mishal Nguyen, Thuy Thi Thu Wheler, Colette Köster, Wolfgang Gerdts, Volker Dar, Arshud Vet Sci Article Innate immune stimulants, especially toll-like receptor (TLR) ligands and agonists, are the main players in the initiation of innate immunity and have been widely studied as alternatives to antibiotics to control infection. In the present study, we characterized the dosage levels of various innate immune stimulants, including unmethylated cytosine-phosphate-guanosine dinucleotide -containing oligodeoxynucleotides (CpG ODN), polyinosinic-polycytidylic acid (poly I:C), cyclic polyphosphazene 75B (CPZ75B), avian beta-defensin 2 (ABD2), and combinations of these reagents given in ovo. Data derived from a series of animal experiments demonstrated that the in ovo administration of 10–50 µg CpG ODN/embryo (on embryonic day 18) is an effective formulation for control of yolk sac infection (YSI) due to avian pathogenic Escherichia coli (E. coli) in young chicks. Amongst the different combinations of innate immune stimulants, the in ovo administration of CpG ODN 10 µg in combination with 15 µg of poly I:C was the most effective combination, offering 100% protection from YSI. It is expected that the introduction of these reagents to management practices at the hatchery level may serve as a potential replacement for antibiotics for the reduction of early chick mortality (ECM) due to YSI/colibacillosis. MDPI 2022-04-22 /pmc/articles/PMC9142911/ /pubmed/35622731 http://dx.doi.org/10.3390/vetsci9050203 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sarfraz, Mishal Nguyen, Thuy Thi Thu Wheler, Colette Köster, Wolfgang Gerdts, Volker Dar, Arshud Characterization of Dosage Levels for In Ovo Administration of Innate Immune Stimulants for Prevention of Yolk Sac Infection in Chicks |
title | Characterization of Dosage Levels for In Ovo Administration of Innate Immune Stimulants for Prevention of Yolk Sac Infection in Chicks |
title_full | Characterization of Dosage Levels for In Ovo Administration of Innate Immune Stimulants for Prevention of Yolk Sac Infection in Chicks |
title_fullStr | Characterization of Dosage Levels for In Ovo Administration of Innate Immune Stimulants for Prevention of Yolk Sac Infection in Chicks |
title_full_unstemmed | Characterization of Dosage Levels for In Ovo Administration of Innate Immune Stimulants for Prevention of Yolk Sac Infection in Chicks |
title_short | Characterization of Dosage Levels for In Ovo Administration of Innate Immune Stimulants for Prevention of Yolk Sac Infection in Chicks |
title_sort | characterization of dosage levels for in ovo administration of innate immune stimulants for prevention of yolk sac infection in chicks |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142911/ https://www.ncbi.nlm.nih.gov/pubmed/35622731 http://dx.doi.org/10.3390/vetsci9050203 |
work_keys_str_mv | AT sarfrazmishal characterizationofdosagelevelsforinovoadministrationofinnateimmunestimulantsforpreventionofyolksacinfectioninchicks AT nguyenthuythithu characterizationofdosagelevelsforinovoadministrationofinnateimmunestimulantsforpreventionofyolksacinfectioninchicks AT whelercolette characterizationofdosagelevelsforinovoadministrationofinnateimmunestimulantsforpreventionofyolksacinfectioninchicks AT kosterwolfgang characterizationofdosagelevelsforinovoadministrationofinnateimmunestimulantsforpreventionofyolksacinfectioninchicks AT gerdtsvolker characterizationofdosagelevelsforinovoadministrationofinnateimmunestimulantsforpreventionofyolksacinfectioninchicks AT dararshud characterizationofdosagelevelsforinovoadministrationofinnateimmunestimulantsforpreventionofyolksacinfectioninchicks |